Monitor early TUDRIQEV prescription and reimbursement data over the next 60 days as the launch ramps; confirmatory IGNYTE-3 trial enrollment updates will be critical for sustained valuation. The recent dilutive offering may cap near-term upside, but the approval catalyst is transformative for the stock.
Price Chart
Executive Summary
Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, announced August 6, 2026. The company is launching within 60 days, recently completed a $150M offering to fund commercialization, and appointed a new CCO. The approval transforms Replimune into a commercial-stage biotech, though the dilutive offering and need for confirmatory trial data temper the outlook.
Key Financial Metrics
Key Facts
- FDA accelerated approval of TUDRIQEV (RP1) + nivolumab for advanced melanoma on August 6, 2026; launch within 60 days
- Q1 FY2026 EPS $-0.72 beat consensus $-0.77 by 6.5%; net loss improved to $69.8M from $86.7M YoY
- Cash, equivalents & short-term investments $195.3M at June 30, 2026; plus $141M net proceeds from August offering extends runway >12 months
- Appointed Michelle DiNapoli as Chief Commercial Officer, effective August 18, 2026
- Completed $150M underwritten public offering on August 10, 2026 (~13% dilution) to support launch and confirmatory trial
Financial Impact
EPS beat of $0.05 (6.5%) vs consensus; net loss narrowed 19.5% YoY; cash burn $73.6M in Q1; $141M net offering proceeds extend runway beyond 12 months
Risk Factors
- Confirmatory trial (IGNYTE-3) overall survival readout not expected until 2030; accelerated approval could be withdrawn if clinical benefit not verified
- Commercial execution risk as a first-time product launcher; competition from existing melanoma therapies
- ~13% dilution from recent offering; potential for additional capital raises if launch costs exceed expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345284 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access